Annexon Biosciences CEO Doug Love considers Guillain-Barré syndrome — also known as GBS — to be the “most unique disease” he’s worked on in 25 years in biotech because of its sudden onset. A rare ...
GeoBroadcast Solutions says the deployment of its two FM booster technologies have now reached 11 markets, including San Francisco, Los Angeles and Chicago. In a new filing with the FCC, GeoBroadcast ...
Paralytic diseases are spreading in Gaza as an Israeli blockade continues to prevent medicine and food from coming in. Since June, 85 suspected cases of Guillain-Barre syndrome (GBS) have been ...
MONTREAL — An investigational targeted immunotherapy for Guillain-Barré syndrome (GBS) more than doubled improvement in disability after 8 weeks compared with placebo and showed sustained benefit at ...
Researchers in Norway studied rates of fatalities and long-term neurodevelopmental disorders among 866 infants diagnosed with GBS infection. Children with GBS meningitis died at higher rates than ...
The last time I wrote about Annexon (ANNX) it was with respect to a Seeking Alpha article entitled "Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place". In this article ...
Group B Streptococcus, which people may call group B strep (GBS), is a type of bacterium that causes GBS disease. GBS can lead to meningitis, which is an infection of the lining of the brain and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results